AVE Shares Avecho Biotechnology Limited
ASX · ASXLast in our picks 2026-10-15 — not in the current list; analysis below is from that screen
Delivery-technology platform provides turnaround potential, though current valuation and liquidity elevate risk.
Future value: $0.03 (+66.67%) · 6-12 months
Signal breakdown
- ▸Recent momentum improvement without strong analyst confirmation.
- ▾Below 50-day MA (-25.45%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 1.53× average — accumulation
- ▸~67% upside to price target
Is AVE a buy right now?
Trend: AVE is trading below the 50-day average (-30.00%), RSI 47 — neutral momentum, with a 3-month return of -26.32%.
Valuation & quality: fundamentals show net margin 0.0%, return on equity -268.2%, revenue growth -89.4% year on year.
Our screen: BUY (score 3) — Delivery-technology platform provides turnaround potential, though current valuation and liquidity elevate risk.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +100.00% | +0.00% | +0.00% | +0.00% | -50.00% |
Fundamentals
Technical signals
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.